

From: [Jones, Tera M](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Wong, Alexis](#)
Subject: New Drug Launch Notification - RINVOQ LQ
Date: Tuesday, June 18, 2024 3:00:17 PM

Some people who received this message don't often get email from tera.jones@abbvie.com. [Learn why this is important](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

Dear Attorney General Donovan,

In accordance with the requirements set forth in Act 193, AbbVie Inc. is providing notice of the June 17, 2024 release into the commercial market of a new prescription medicine, RINVOQ LQ (Upadacitinib).

RINVOQ LQ is a prescription medicine used to treat pediatric patients two years or older with polyarticular juvenile idiopathic arthritis and psoriatic arthritis. The medicine's wholesale acquisition cost exceeds the threshold set for a specialty drug under the Medicare Part D program.

Also, per Act 193, we will be sending the information required within the 30-calendar day timeline.

Regards,

TERA M. JONES (SHE/HER)

Associate Compliance Officer, OEC Operations
Global Transparency, Governance & Reporting



1 North Waukegan Road

AP30-4

North Chicago, IL 60064

OFFICE +1 847-937-3856

CELL +1 847-970-2970

EMAIL tera.arana@abbvie.com